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ABSTRACT  
An olomoucine analogues of 2-[(1-substituted)-2,6-dioxo-2,3,6,7–tetrahydro-1H-purin-8-ylsulfanyl]-N-substituted 
acetamide 6a-g and 7a-g, 1-substituted-8-[2-(4-substituted phenyl)-2-oxoethylsulphanyl]-3,7-dihydro-1H-purine-2,6-diones 
9a-g and 10a-g, 3-(2-substituted benzyl)-6-(4-substituted phenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 11a-g and 12a-g and 
their isosteres 3-substituted benzyl-5-methyl-7-substituted-1H-pyrido[2,3-d]pyrimidine-2,4-dione 13a-c and 14a-c were 
designed and synthesized. The target compounds 11a-g and 12a-g were prepared by cyclodehydration of 9a-g and 10a-g 
in PPA, while 13a-c and 14a-c were synthesized by condensation of 6-amino-3-(2-substituted benzyl)-1H-pyrimidine-2,4-
dione 1a or 1b and the appropriate acylacetone in glacial acetic acid. Structures of the new compounds were verified on 
the basis of their IR, 
1
H NMR, MS, HRMS and elemental analyses. The newly synthesized compounds were tested for 
their anticancer activity and most of the tested compounds showed good to excellent inhibition activity against the tested 
human breast cancer cell line MCF-7 in comparison to doxorubicin as a reference drug. 
KEYWORDS: olomoucine; cyclin-depenent kinase; synthesis; anticancer 
INTRODUCTION 
Cancer is a class of diseases characterized by out-of-control cell growth. Cancers can arise from both genetic and lifestyle 
factors that lead to abnormal regulation in the growth of particular stem cell populations or by the undifferentiation of 
mature cell types 
1
. This aberrant control of cell division can lead to either a benign tumour, which does not spread to other 
parts of the body and as such is rarely life threatening or to a malignant tumour which can invade other organs, move to 
other bodily locations (metastasise) and become life threatening 
1
. Although the development of novel targeted antitumor 
drugs have obtained important progress in recent years, cancer remains a major leading cause of death in the world due 
to drug resistance or undesirable toxic effects 
2
. At present, a wide range of cytotoxic drugs with different mechanisms of 
action are used to treat human cancer, either alone or in combination 
3
. In addition, numerous compounds are also in 
different phases of clinical trials. The main drawback of these cytotoxic drugs is that they do not discriminate between 
cancerous and normal cell types and are accompanied by toxic side effects that are often cumulative and dose limiting 
3
. 
Despite the enormous progress made in recent years in the understanding of the mechanisms involved in cancer onset 
and propagation and apart from classical cytotoxic-based therapies, there has been an active search for new approaches, 
such as protein kinase inhibition 
4
. 
Cyclin-dependent kinases (cdks) play important roles in cell cycle regulation. Their sequential activation ensures the 
correct timing and ordering of events required for cell cycle progression 
5
. CDKs control the cell division cycle (cdc). These 
kinases and their regulators are frequently deregulated in human tumours 
6
. The purine ring presents in the structure of 
ATP itself, so it is hardly surprising that amongst the first Cdk inhibitors to be described are 6-dimethylaminopurine and 
isopentenyladenine which are purine scaffold containing inhibitors 
4
. By structural analogy  of 6-dimethylaminopurine, 
which was found to inhibit mitosis of sea urchin embryos without inhibiting protein synthesis, was a substituted purine, 
olomoucine [2-(2-hydroxyethylamino)-6-benzylamino-9-methyl-purine], chart 1 
6
. Trisubstituted purines in positions C-2, 
C-6 and N-9 were the most active, and olomoucine was identified as a specific cdk inhibitor which was found to block 
selectively CDK1, CDK2 and CDK5 kinases at micromolar concentrations 
4, 7
. In addition, the pyrimidine and purine ring 
systems undoubtedly belong to the most ubiquitous heterocycles in nature, as they represent the main structure of many 
biologically significant compounds, including nucleosides and nucleotides. Several of the latter heterocycles possess a 
multitude of pronounced biological activities 
8
. These derivatives have been utilized extensively in medicinal chemistry due 
to their privileged structure that show various pharmacological activities, such as, anticancer 
9-15
, anti-inflammatory 
16-20
, 
anticonvulsant 
21-23
 and antibacterial 
12, 18, 24-26
 and antidiabetic activities through inhibition of phosphoenolpyruvate 
carboxykinase (PEPCK) 
27, 28
 among others. Moreover, recently 1,8-disubstituted purine-2,6-diones [AH-216 (II), AH-217 
(III); chart 2] were reported to possess potent antitumor activity against breast cancer and leukemia 
10
. For these reasons, 
many analogues and derivatives of purine and pyrimidine have been synthesised and developed as pharmacologically 
active compounds 
8
. 
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In view of the above-mentioned facts and in continuation of our interest in the synthesis of new heterocyclic compounds 
comprising in their skeletons the purine-2,6-dione moieties and screening of their biological activities, herein we report the 
synthesis and anticancer activity of new purine-diones and their isosters pyridopyrimidine diones. 
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Chart 1; structure of olomoucine 
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Chart 2; structures of AH-216 (II) and AH-217 (III) 
MATERIALS AND METHODS 
Chemistry 
Materials 
Melting points were determined on an electrothermal melting point apparatus (Stuart Scientific, SMP3, Staffordshire, UK) 
and were uncorrected. Pre-coated silica gel plates (Kieselgel 0.25 mm, 60G F254, Merck, Darmstadt, Germany) were 
used for TLC monitoring of reactions using CH2Cl2/CH3OH 9:1 as a mobile phase. Visualization of the spots was effected 
using an ultraviolet lamp (Spectroline, model CM-10, Seattle, USA) (λ= 254 nm) and/or iodine stain. IR spectra were 
carried out as KBr discs on a Shimadzu IR-470 Spectrophotometer (Shimadzu, Kyoto, Japan) at Faculty of Pharmacy, 
Assiut University. 
1
H NMR spectra were performed on a JEOL JNMLA series FT NMR system (400 MHz, JEOL, Tokyo, 
Japan) at the Assiut University Unit of Trace Analyses or on a Varian spectrometer (300 MHz, Varian, CA, USA) at the unit 
of Microanalysis, Faculty of Science, Cairo University or on a Varian EM-360L NMR spectrometer (60 MHz, Varian, CA, 
USA) at Faculty of Pharmacy, Assiut University, Assiut. Chemical shifts are expressed in δ-values (ppm) relative to 
tetramethylsilane (TMS) as an internal standard using DMSO-d6 as a solvent and deuterium oxide was used for the 
detection of exchangeable protons. Mass spectra were recorded with a Gas Chromatography Mass, Quadruple-2010 Plus 
(Shimadzu, Kyoto, Japan) at the unit of Microanalysis, Faculty of Science, Cairo University. ESI-HRMS were determined 
using Bruker Bio TOF III (ESI-TOF, Bruker, MA, USA) in the Genomic Research Centre, Academia Sinica, Taiwan. 
Elemental microanalyses were performed on a Vario elemental analyzer III (Vario, Hanau, Germany) at the unit of 
Microanalysis, Faculty of Science, Cairo University. 
Compounds 6-amino-3-(2-substituted benzyl)-1H-pyrimidine-2,4-dione 1a,b, 2-[(1-substituted)-2,6-dioxo-2,3,6,7–
tetrahydro-1H-purin-8-ylsulfanyl]-N-substituted-acetamide 6a-g&7a-g and 1-substituted-8-[2-(4-substituted phenyl)-2-
oxoethylsulphanyl]-3,7-dihydro-1H-purine-2,6-diones 9a-g&10a-g were prepared as reported in a recent pervious 
publication 
29
. 
Methods 
General procedure for the preparation of 3-(2-Substituted benzyl)-6-(4-substituted phenyl)-
1H-thiazolo[2,3-f]purine -2,4-dione (11a-g, 12a-g)  
To a stirred freshly prepared polyphosphoric acid formed from phosphorus pentoxide (8.00 g) and phosphoric acid (6.00 
mL), the appropriate 1-substituted-8-[2-(4-substituted phenyl)-2-oxoethylsulfanyl]-3,7-dihydro-1H-purine-2,6-diones (9a-g 
and 10a-g) (5.30 mmol) was added, and the reaction mixture was heated at 130-140ºC for 5-6 h (except for 9f and 10f 
were heated at 110-120ºC for 7-8 h). The reaction mixture was cooled, poured into ice-water and neutralized with 
saturated sodium carbonate solution. The precipitated solid was filtered, washed with water, dried, and crystallized from 
absolute ethanol to afford the target products 11a-g and 12a-g. 
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3.1.1.1.1.   3-Benzyl-6-phenyl-1H-thiazolo[2,3-f]purine-2,4-dione 11a 
Buff crystals, m.p. 253-255ºC, yield 50%, IR (KBr) ύ (cm
-1
) 3320 (N-H); 3045 (Ar-H); 2895 (C-H aliphatic); 1699, 1650 
(C=O); 743, 690 (Ar-H); 
1
H NMR (400 MHz, DMSO-d6): δ 4.89 (s, 2H, N1-CH2), 7.14-7.54 (m, 10H, Ar-H), 7.28 (s, 1H, C7-
H), 12.25 (s, 1H, N3-H, exchangeable with D2O); Anal. Calc. (%) for for C20H14N4O2S: C, 64.16; H, 3.77; N, 14.96; Found: 
C, 64.19; H, 4.00; N, 14.72. 
3.1.1.1.2. 3-Benzyl-6-(4-bromophenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 11b 
Buff crystals, m.p. 298-299ºC, yield 88%, IR (KBr) ύ (cm
-1
) 3405 (N-H); 3090 (Ar-H); 2990 (C-H aliphatic); 1696, 1664 
(C=O); 806, 736, 710 (Ar-H), 575 (C-Br); 
1
H NMR (400 MHz, DMSO-d6): δ 4.91 (s, 2H, N1-CH2), 7.14-7.26 (m, 5H, Ar-H), 
7.33 (s, 1H, C7-H), 7.50 (d, J = 8.4 Hz, 2H, 3′,5′Ar-H), 7.60 (d, J = 8.4 Hz, 2H, 2′,6′Ar-H), 12.27 (s, 1H, N3-H, 
exchangeable with D2O); ESI-HRMS (m/z): 453.0028 (M
+
+1) (calcd. 453.0015). 
3.1.1.1.3. 3-Benzyl-6-(4-chlorophenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 11c 
Buff crystals, m.p. 243-245ºC, yield 68%, IR (KBr) ύ (cm
-1
) 3400 (N-H); 3095 (Ar-H); 2900 (C-H aliphatic); 1695, 1665 
(C=O); 1084 (C-Cl); 830, 735, 694 (Ar-H); 
1
H NMR (300 MHz, DMSO-d6): δ 5.12 (s, 2H, N1-CH2), 7.11-7.32 (m, 5H, Ar-H), 
7.63 (d, J = 8.4 Hz, 2H, 3′,5′Ar-H), 7.76 (s, 1H, C7-H), 8.21 (d, J = 8.4 Hz, 2H, 2′,6′Ar-H), 12.00 (s, 1H, N3-H, 
exchangeable with D2O; EI-MS: m/z: 408.05 (M
+
, 62.43%), 410.00 (M
+
+2, 25.32%), 91.05 (100%). Anal. Calc. (%) for 
C20H13ClN4O2S: C, 58.75; H, 3.20; N, 13.70; Found: C, 58.67; H, 2.99; N, 13.60. 
3.1.1.1.4. 3-Benzyl-6-(4-fluorophenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 11d 
Buff crystals, m.p. 222-224ºC, yield 63%, IR (KBr) ύ (cm
-1
) 3400 (N-H); 3055 (Ar-H); 2950 (C-H aliphatic); 1700, 1661 
(C=O); 1223 (C-F); 832, 732, 694 (Ar-H); 
1
H NMR (60 MHz, DMSO-d6): δ 5.10 (s, 2H, N1-CH2), 7.10 (s, 1H, C7-H), 7.20-
7.83 (m, 9H, Ar-H), 12.50 (s, 1H, N3-H, exchangeable with D2O); EI-MS: m/z: 392.00 (M
+
, 91.30%), 91.00 (100%); ESI-
HRMS (m/z): 393.0813 (M
+
+1) (calcd. 393.0816). 
3.1.1.1.5. 3-Benzyl-6-p-tolyl-1H-thiazolo[2,3-f]purine-2,4-dione 11e 
Buff crystals, m.p. 278-280ºC, yield 72%, IR (KBr) ύ (cm
-1
) 3440 (N-H); 3090 (Ar-H); 2955 (C-H aliphatic); 1700, 1651 
(C=O); 802, 741, 694 (Ar-H); 
1
H NMR (60 MHz, DMSO-d6): δ 2.43 (s, 3H, CH3), 5.07 (s, 2H, N1-CH2), 7.17-7.67 (m, 10H, 
Ar-H, C7-H), 12.40, (s, 1H, N3-H, exchangeable with D2O); Anal. Calc. (%) for C21H16N4O2S: C, 64.93; H, 4.15; N, 14.42; 
Found: C, 64.81; H, 3.86; N, 14.28. 
3.1.1.1.6. 3-Benzyl-6-(4-methoxyphenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 11f 
Buff crystals, m.p. 200-202ºC, yield 58%, IR (KBr) ύ (cm
-1
) 3410 (N-H); 3055 (Ar-H); 2900 (C-H aliphatic); 1697, 1651, 
1620 (C=O); 1250, 1060 (C-O); 813, 743, 711 (Ar-H); 
1
H NMR (60 MHz, DMSO-d6): δ 3.87 (s, 3H, OCH3), 5.07 (s, 2H, N1-
CH2), 6.98 (d, J = 8.2 Hz, 2H, 3′,5′Ar-H), 7.10 (s, 1H, C7-H), 7.30 (s, 5H, Ar-H), 7.57 (d, J = 8.2 Hz, 2H, 2′,6′Ar-H), 12.33 
(s, 1H, N3-H, exchangeable with D2O); ESI-HRMS (m/z): 405.1012 (M
+
+1) (calcd. 405.1016). 
3.1.1.1.7. 3-Benzyl-6-(4-nitrophenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 11g 
Buff crystals, m.p. 299-301ºC, yield 85%, IR (KBr) ύ (cm
-1
) 3445 (N-H); 3115 (Ar-H); 2950 (C-H aliphatic); 1698, 1653 
(C=O); 1503, 1342 (NO2); 833, 767, 702 (Ar-H); 
1
H NMR (60 MHz, DMSO-d6): δ 5.03 (s, 2H, N1-CH2), 7.23 (s, 5H, Ar-H), 
7.33 (s, 1H, C7-H), 7.88 (d, J = 8.8 Hz, 2H, 2′,6′ Ar-H), 8.32 (d, J = 8.8 Hz, 2H, 3′,5′ Ar-H), 12.50 (s, 1H, N3-H, 
exchangeable with D2O); ESI-HRMS (m/z): 420.0762 (M
+
+1) (calcd. 420.0761); Anal. Calc. (%) for C20H13N5O4S: C, 
57.27; H, 3.12; N, 16.70; Found: C, 57.02; H, 3.38; N, 16.60. 
3.1.1.1.8. 3-(2-Fluorobenzyl)-6-phenyl-1H-thiazolo[2,3-f]purine-2,4-dione 12a 
Buff crystals, m.p. 326-328ºC, yield 95%, IR (KBr) ύ (cm
-1
) 3420 (N-H); 3035 (Ar-H); 2865 (C-H aliphatic); 1702, 1644 
(C=O); 1219 (C-F); 739, 691 (Ar-H); 
1
H NMR (60 MHz, DMSO-d6): δ 4.93 (s, 2H, N1-CH2), 6.53-7.57 (m, 9H, Ar-H), 7.40 
(s, 1H, C7-H), 12.50 (s, 1H, N3-H, exchangeable with D2O); Anal. Calc. (%) for C20H13FN4O2S: C, 61.22; H, 3.34; N, 
14.28; Found: C, 61.00; H, 3.58; N, 14.32. 
3.1.1.1.9. 6-(4-Bromophenyl)-3-(2-fluorobenzyl)-1H-thiazolo[2,3-f]purine-2,4-dione 
12b 
Buff crystals, m.p. 313-315ºC, yield 67%, IR (KBr) ύ (cm
-1
) 3380 (N-H); 3110 (Ar-H); 2940 (C-H aliphatic); 1696, 1656 
(C=O); 1557 (N-H); 1220 (C-F); 809, 748 (Ar-H); 540 (C-Br); 
1
H NMR (60 MHz, DMSO-d6): δ 5.07 (s, 2H, N1-CH2), 6.77-
7.77 (m, 8H, Ar-H), 7.30 (s, 1H, C7-H), 12.20 (br s, 1H, N3-H, exchangeable with D2O); EI-MS: m/z: 469.90 (M
+
, 87.15%), 
471.90 (M
+
+2, 77.97%), 109.00 (100%); Anal. Calc. (%) for C20H12BrFN4O2S: C, 50.97; H, 2.57; N, 11.89; S, 6.80; Found: 
C, 51.18; H, 2.60; N, 11.74; S, 6.57. 
3.1.1.1.10. 6-(4-Chlorophenyl)-3-(2-fluorobenzyl)-1H-thiazolo[2,3-f]purine-2,4-dione 
12c 
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Buff crystals, m.p. 195-197ºC, yield 50%, IR (KBr) ύ (cm
-1
) 3470 (N-H); 3045 (Ar-H); 2895 (C-H aliphatic); 1694, 1656 
(C=O); 1219 (C-F); 1083 (C-Cl); 830, 747 (Ar-H); 
1
H NMR (60 MHz, DMSO-d6): δ 5.10 (s, 2H, N1-CH2), 7.00-7.80 (m, 9H, 
Ar-H, C7-H), 12.30 (br s, 1H, N3-H, exchangeable with D2O); Anal. Calc. (%) for C20H12ClFN4O2S: C, 56.28; H, 2.83; N, 
13.13; Found: C, 56.00; H, 2.73; N, 12.88. 
3.1.1.1.11. 3-(2-Fluorobenzyl)-6-(4-fluorophenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 
12d 
Buff crystals, m.p. 281-283ºC; yield 80%, IR (KBr) ύ (cm
-1
) 3370 (N-H); 3062 (Ar-H); 2875 (C-H aliphatic); 1693, 1654 
(C=O); 1222 (C-F); 819, 746 (Ar-H); 
1
H NMR (60 MHz, DMSO-d6): δ 5.07 (s, 2H, N1-CH2), 7.00-7.93 (m, 9H, Ar-H, C7-H), 
12.30 (s, 1H, N3-H, exchangeable with D2O); Anal. Calc. (%) for C20H12F2N4O2S: C, 58.53; H, 2.95; N, 13.65; S, 7.81; 
Found: C, 58.26; H, 3.18; N, 13.42; S, 7.34. 
3.1.1.1.12. 3-(2-Fluorobenzyl)-6-p-tolyl-1H-thiazolo[2,3-f]purine-2,4-dione 12e 
Buff crystals, m.p. 295-297ºC; yield 89%, IR (KBr) ύ (cm
-1
) 3360 (N-H); 3045 (Ar-H); 2945 (C-H aliphatic); 1697, 1654 
(C=O); 1221 (C-F); 809, 745 (Ar-H); 
1
H NMR (300 MHz, DMSO-d6): δ 2.35 (s, 3H, CH3), 4.96 (s, 2H, N1-CH2), 6.97-7.19 
(m, 5H, Ar-H), 7.22 (d, J = 8.2 Hz, 2H, 3′,5′Ar-H), 7.24 (s, 1H, C7-H), 7.42 (d, J = 8.2 Hz, 2H, 2′,6′Ar-H), 12.27 (br s, 1H, 
N3-H, exchangeable with D2O); EI-MS: m/z: 406.00 (M
+
, 100%); Anal. Calc. (%) for C21H15FN4O2S: C, 62.06; H, 3.72; N, 
13.79; S, 7.89; Found: C, 61.94; H, 3.54; N, 13.46; S, 7.69. 
3.1.1.1.13. 3-(2-Fluorobenzyl)-6-(4-methoxyphenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 
12f 
Buff crystals, m.p. 242-244ºC; yield 51%, IR (KBr) ύ (cm
-1
) 3435 (N-H); 3045 (Ar-H); 2930 (C-H aliphatic); 1697, 1663 
(C=O); 1249, 1025 (C-O); 1212 (C-F); 818, 755 (Ar-H); 
1
H NMR (60 MHz, DMSO-d6): δ 3.83 (s, 3H, OCH3), 5.07 (s, 2H, 
N1-CH2), 6.67-7.27 (m, 7H, Ar-H, C7-H), 7.47 (d, J = 8.6 Hz, 2H, 2′,6′Ar-H), 12.33 (br s, 1H, N3-H, exchangeable with 
D2O); ESI-HRMS (m/z): 423.0925 (M
+
+1) (calcd. 423.0922). 
3.1.1.1.14. 3-(2-Fluorobenzyl)-6-(4-nitrophenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 12g 
Buff crystals, m.p. 300-302ºC; yield 59%, IR (KBr) ύ (cm
-1
) 3390 (N-H); 3100 (Ar-H); 2950 (C-H aliphatic); 1701, 1662 
(C=O); 1537, 1333 (NO2); 1211 (C-F); 820, 746 (Ar-H); 
1
H NMR (400 MHz, DMSO-d6): δ 4.93 (s, 2H, N1-CH2), 6.63-7.23 
(m, 4H, Ar-H), 7.27 (s, 1H, C7-H), 7.76 (d, J = 8.4 Hz, 2H, 2′,6′Ar-H), 8.20 (d, J = 8.4 Hz, 2H, 3′,5′Ar-H), 12.30 (br s, 1H, 
N3-H, exchangeable with D2O); ESI-HRMS (m/z): 438.0666 (M
+
+1) (calcd. 438.0667). 
3.1.1.2. 3-substituted benzyl-5-methyl-7-substituted-1H-pyrido[2,3-d]pyrimidine-2,4-
dione 13a-c,14 a-c 
6-Amino-3-(2-substituted benzyl)-1H-pyrimidine-2,4-dione 1a or 1b (1.50 mmol) and the appropriate acylacetone 
derivative (1.50 mmol) were dissolved in glacial acetic acid (10.00 mL) and the solution was refluxed for 3-4 h. The 
reaction mixture was poured in an ice-cooled water and was made basic to litmus with ammonia solution (25%). The 
precipitate was filtered, washed with water and recrystallized from absolute ethanol to afford the target products  13a-c and 
14a-c. 
3.1.1.2.1. 3-Benzyl-5,7-dimethyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione 13a 
Yellow crystals, m.p. 248-250ºC; yield 52%, IR (KBr) ύ (cm
-1
) 3395 (N-H); 3185 (Ar-H); 2960 (C-H aliphatic); 1700, 1656 
(C=O); 750, 700 (Ar-H); 
1
H NMR (60 MHz, DMSO-d6): δ 2.57 (s, 3H, CH3), 2.72 (s, 3H, CH3), 5.10 (s, 2H, N3-CH2), 6.63 
(s, 1H, C6-H), 7.00-7.57 (m, 5H, Ar-H), 10.37 (s, 1H, N1-H, exchangeable with D2O); EI-MS: m/z: 280.90 (M
+
, 100%); 
Anal. Calc. (%) for C16H15N3O2: C, 68.31; H, 5.37; N, 14.94; Found: C, 68.22; H, 5.71; N, 14.77. 
3.1.1.2.2. 3-Benzyl-5-methyl-7-phenyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione 13b 
Yellow crystals, m.p. 187-189ºC; yield 55%, IR (KBr) ύ (cm
-1
) 3390 (N-H); 3050 (Ar-H); 2950 (C-H aliphatic); 1690, 1647 
(C=O); 750, 691 (Ar-H); 
1
H NMR (60 MHz, DMSO-d6): δ 2.73 (s, 3H, CH3), 5.10 (s, 2H, N3-CH2), 6.67 (s, 1H, C6-H), 6.93-
8.90 (m, 10H, Ar-H), 10.83 (s, 1H, N1-H, exchangeable with D2O); Anal. Calc. (%) for C21H17N3O2: C, 73.45; H, 4.99; N, 
12.24; Found: C, 73.11; H, 4.56; N, 12.30. 
3.1.1.2.3.     3-Benzyl-7-(4-chlorophenyl)-5-methyl-1H-pyrido[2,3-d]pyrimidine-2,4-
dione 13c 
Yellow crystals, m.p. 167-169ºC; yield 55% , IR (KBr) ύ (cm
-1
) 3375 (N-H); 3100 (Ar-H); 2950 (C-H aliphatic); 1697, 1645 
(C=O); 1084 (C-Cl); 811, 760, 691 (Ar-H); 
1
H NMR (400 MHz, DMSO-d6): δ 2.75 (s, 3H, CH3), 5.05 (s, 2H, N3-CH2), 7.24-
7.33 (m, 5H, Ar-H), 7.61 (d, J = 8.4 Hz, 2H, 3′,5′Ar-H), 7.75 (s, 1H, C6-H), 8.19 (d, J = 8.4 Hz, 2H, 2′,6′Ar-H), 11.99 (s, 1H, 
N1-H, exchangeable with D2O); ESI-HRMS (m/z): 378.1014 (M
+
+1) (calcd. 378.1004). 
3.1.1.2.4.  3-(2-Fluorobenzyl)-5,7-dimethyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione 14a 
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Yellow crystals, m.p. 253-255ºC; yield 61%, IR (KBr) ύ (cm
-1
) 3350 (N-H); 3080 (Ar-H); 2995 (C-H aliphatic); 1709, 1651 
(C=O); 1222 (C-F); 750 (Ar-H); 
1
H NMR (300 MHz, DMSO-d6): δ 2.51 (s, 3H, CH3), 2.63 (s, 3H, CH3), 5.08 (s, 2H, N3-
CH2), 6.89 (s, 1H, C6-H), 7.10-7.30 (m, 4H, Ar-H), 11.85 (s, 1H, N1-H, exchangeable with D2O); EI-MS: m/z: 299.00 (M
+
, 
48.23%), 109.00 (100%); Anal. Calc. (%) for C16H14FN3O2: C, 64.21; H, 4.71; N, 14.04; Found: C, 64.00; H, 4.46; N, 14.35. 
3.1.1.2.5. 3-(2-Fluorobenzyl)-5-methyl-7-phenyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione 
14b 
Yellow crystals, m.p. 149-151ºC; yield 58%, IR (KBr) ύ (cm
-1
3435 (N-H); 3085 (Ar-H); 2950 (C-H aliphatic); 1710, 1652 
(C=O); 1228 (C-F); 766, 690 (Ar-H); 
1
H NMR (60 MHz, DMSO-d6): δ 2.03 (s, 3H, CH3), 5.73 (s, 2H, N3-CH2), 7.33-8.03 
(m, 10H, Ar-H, C6-H), 10.33 (s, 1H, N1-H, exchangeable with D2O); EI-MS: m/z: 361.00 (M
+
, 9.86%), 84.00 (100%); Anal. 
Calc. (%) for C21H16FN3O2: C, 69.80; H, 4.46; N, 11.63; Found: C, 69.60; H, 4.59; N, 11.28. 
3.1.1.2.6. 7-(4-Chlorophenyl)-3-(2-fluorobenzyl)-5-methyl-1H-pyrido[2,3-
d]pyrimidine-2,4-dione 14c 
Yellow crystals, m.p. 116-118ºC; yield 50%, IR (KBr) ύ (cm
-1
) 3430 (N-H); 3050 (Ar-H); 2995 (C-H aliphatic); 1702, 1650 
(C=O); 1221 (C-F); 1083 (C-Cl); 839, 754 (Ar-H); 
1
H NMR (300 MHz, DMSO-d6): δ 2.76 (s, 3H, CH3), 5.12 (s, 2H, N3-
CH2), 7.09-7.32 (m, 5H, Ar-H), 7.63 (d, J = 8.4 Hz, 2H, 3′,5′Ar-H), 7.76 (s, 1H, C7-H), 8.20 (d, J = 8.4 Hz, 2H, 2′,6′Ar-H), 
11.98 (s, 1H, N1-H, exchangeable with D2O); EI-MS: m/z: 394.90 (M
+
, 26.90%), 396.90 (M
+
+2, 10.13%), 109.00 (100%); 
Anal. Calc. (%) for C21H15ClFN3O2: C, 63.72; H, 3.82; N, 10.62; Found: C, 63.83; H, 4.00; N, 10.28. 
3.2. Anticancer Activity 
The anticancer activity was carried out at the National Cancer Institute, Cairo University. 4a, 4b, 6c, 7c, 9c, 10a, 10c, 12a, 
13a, 13b and 14a, were chosen to test for their anticancer activity against human breast carcinoma MCF-7 cell line in 
comparison to Doxorubicin as a reference drug. 
3.2.1. Drugs, chemicals and reagents 
The referent anticancer drug Doxorubicin was purchased from Sigma (Perth, Western Australia) and used as positive 
control. Test compounds were dissolved in 20% DMSO in 1 mg/mL concentration. Serial dilution of the compounds were 
made to reach final concentrations of 5, 12.50, 25, 50 µg/mL. All the chemical used are of high analytical grade and were 
obtained from Sigma-Aldrich. 
3.2.2.  Tumor cell lines and culture conditions 
The breast carcinoma cell line was obtained frozen in liquid nitrogen (-180
°
C) from the American Type Culture Collection 
and was maintained in the National Cancer Institute, Cairo, Egypt, by serial sub-culturing. MCF-7 was grown as a 
monolayer culture in RPMI-1640 medium supplemented in 10% Fetal Bovine Serum (FBS) and 1% 
Penicillin/Streptomycin. The cell line was then incubated at 37
°
C, 5% CO2, 95% air and high humidity atmosphere in water 
jacketed incubator (Revco, GS laboratory equipment, RCO 3000 TVBB, USA). Cell line was regularly subcultures to 
maintain in the exponential growth phase. Sterile conditions were strictly attained by working under equipped laminar flow 
(Microflo Laminar flow cabinet, Hamsphire SPP 105a, USA). 
3.2.3. Cytotoxic activity of test compounds 
The cytotoxicity of the tested compounds were tested on MCF-7 cell line using SRB assay according to a reported 
procedure 
30
. Cells were seeded in 96-well microtiter plates and left to attach to the plates for 24 h. After 24 h, cells were 
incubated with the appropriate concentration ranges of drugs (0.00, 5.00, 12.50, 25.00 and 50.00 μg/mL) and incubation 
was continued for 24, 48 and 72 h. Control cells were treated with vehicle alone. For each drug concentration, 4 wells 
were used. Following 24, 48 and 72 h treatment, the cells were fixed with 50 μL cold 50% trichloroacetic acid for 1 h at 
4
°
C. Wells were washed 5 times with distilled water and stained for 30 min at room temperature with 50 μL 0.4% 
Sulphorhodamine-B (SRB) dissolved in 1% acetic acid, then washed 4 times with 1% acetic acid. The plates were air-
dried and the dye was solubilized with 100 μL/well of 10 mM tris base (pH 10.5) for 5 min on a shaker (Orbital shaker OS 
20, Boeco, Germany) at 1600 rpm. The optical density (O.D.) of each well was measured spectrophotometrically at 564 
nm with an enzyme linked immunosorbent assay (ELIZA) microplate reader (Meter tech. Σ 960, U.S.A.). The mean 
background absorbance was automatically subtracted and mean values of each drug concentration was calculated. The 
percentage of cell survival was calculated as follows: Survival fraction = O.D. (treated cells)/O.D. (control cells). The IC50 
values (the concentrations of thymoquinone required to produce 50% inhibition of cell growth) were calculated using 
commercially available software (GraphPad Prizm). All experiments were carried out in triplicate and the data are listed in  
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Table 1: Cytotoxic activity of compounds 4a, 4b, 6c, 7c, 9c, 10a, 10c, 12a, 13a, 13b, 14a and Doxorubicin on 
 MCF-7 cell line. 
Compd. 
No. 
IC50 
µmol/mL 
Compd. 
No. 
IC50 
µmol/mL 
Doxorubicin 7.73
 
10a 56.82 
4a 15.64 10c 10.04 
4b 19.95 12a 14.00 
6c 18.35 13a 13.41 
7c 8.87 13b 11.98 
9c 7.25 14a 69.54 
3.3. Molecular Modeling 
Pharmacophore studies were carried out on Dell Precision™ T3600 Workstation [Intel Xeon E5-1660 3.3GHz, 16GB 
1600MHz DDR3, ECC RDIMM 1TB (7200RPM), 1GB NVIDIA Quadro 2000, Windows 7 Professional (64 Bit)]. The 
training set was built from 30 compounds using the Molecular Operating Environment (MOE) package version 2011.10 
(Chemical Computing Group, Inc. Molecular Operating Environment (MOE). CCG, Montreal, Canada. 2011). A common-
features pharmacophore model was derived with the HipHop module of Catalyst using the Accelrys Discovery Studio 2.5 
(DS) software. For all compounds in the training set, energy minimization process was performed with CHARMM 
forcefield. Poling algorithm 
31
 was applied to generate a maximum of 255 diverse conformations with the energy threshold 
of 20 kcal mol
-1
 above the calculated energy minimum for every compound in the dataset. These conformers were 
generated using Diverse Conformer Generation protocol running with Best/Flexible conformer generation option as 
available in DS. The most active compound (M1) was considered as ‘reference compound’ specifying a ‘Principal’ value of 
2 and a ‘MaxOmitFeat’ value of 0, meaning its structure and conformation would have the strongest influence in the model 
building phase. The ‘Principal’ value and ‘MaxOmitFeat’ value for the remaining active compounds were set to 1 and 1, 
respectively. The inactive compounds were given a ‘Principal’ value and ‘MaxOmitFeat’ value of 0 and 1, respectively. 
Feature Mapping protocol was used to identify the common chemical groups present in the training set 
compounds. As predicted, hydrogen bond acceptor (HBA), hydrogen bond donor (HBD), hydrophobic (HY), 
and RING_AROMATIC (RA), Positive_Ionizable, Negative_Ionizable features were selected during the 
pharmacophore generation. Misses specifies the number of molecules that do not have to map to all features 
in the hypothesis. FeatureMisses, the number of maximal molecules which do not have to map to each 
feature in generated hypothesis. CompleteMisses specify the number of molecules that do not have to map to 
any features in the hypothesis. The Misses, FeatureMisses and CompleteMisses were set to 2, 2 and 2, 
respectively. The minimum inter-feature distance was chosen to be not less than 3.0 Å.  
3.3.1. Ligand Pharmacophore Mapping 
The Ligand Pharmacophore Mapping protocol compares a set of ligands to a pharmacophore. A set of 50 synthesized 
compounds have been mapped against Hypothesis-1 pharmacophore, using the following parameters: Maximum omitted 
features to be 2 and using Flexible fitting method. 
3.4.  Flow Cytometric Analysis of Apoptosis and cell cycle analysis  
The most active compounds as anticancer agent, compounds 6c, 7c, 9c, 10c, 12a, 13a and 14a, were selected as 
representatives for testing the flow cytometric analysis in two different concentrations each; at 25 μg/mL and at its 
corresponding IC50 in μg/mL 
Flow cytometry was performed with the FACSCalibur system (BD, San Jose, CA, USA). All fluorocytometric data were 
subsequently analysed and displayed with CELLQUEST software (BD, San Jose, CA, USA). Each analysis included 
measurements from a minimum of 20 000 cells. 
After treatment with tested drugs, MCF-7 cells were fixed and permeabilized with 70 % ice-cold ethanol for at least 1 h and 
then washed twice in PBS. DNA was stained by incubating the cells at 37°C for 1 h in 40 μg/mL propidium iodide and 100 
μg/mL DNase-free Rnase in PBS. Samples were analyzed by flow cytometry using a FACSCalibur flow cytometer (BD-
Pharmingen). The FL2 red fluorescence channel was assessed on a linear scale, and the percentage of cells undergoing 
apoptosis was determined as the percentage of hypodiploid cells (sub G0/G1 peak). Dead cells were identified using the 
Trypan blue exclusion test. 
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4.  RESULTS AND DISCUSSION 
4.1. Chemistry 
The key intermediates, 6-amino-3-benzyl-1H-pyrimidine-2,4-dione 1a&b, 1-substituted-8-thioxo-3,7,8,9-tetrahydropurine-
2,6-dione 4a&b  and their derivatives 2-[(1-substituted)-2,6-dioxo-2,3,6,7–tetrahydro-1H-purin-8-ylsulfanyl]-N-substituted 
acetamide 6a-g and 7a-g and 1-substituted-8-[2-(4-substituted phenyl)-2-oxoethylsulfanyl]-3,7-dihydro-1H-purine-2,6-
diones 9a-g and 10 a-g were prepared according to reported procedure 
29
. The general route to obtain the target 3-(2-
substituted benzyl)-6-(4-substituted phenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 11a-g and 12a-g and their isosteres 3-
substituted benzyl-5-methyl-7-substituted-1H-pyrido[2,3-d]pyrimidine-2,4-dione 13a-c and 14a-c is presented in Schemes 
1 and 2. 
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Scheme 1: Synthesis of anilide derivatives 6a-g and 7a-g, phenacyl bromide derivatives 9a-g and 10a-g and their 
cyclized thiazolo[2,3-f]purine diones 11a-g and 12a-g 
 
 
 
 
 
 
 
 
 
 
Scheme 2: Synthesis of pyrido[2,3-d]pyrimidine dione derivatives 13a-c and 14a-c 
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Trials to use glacial acetic acid or ethanolic solution of hydrochloric acid in cyclodehydration of some 1,8-disubstituted 
purine-2,6-diones to obtain the required 3,6-disubstituted thiazolo[2,3-d]purine-2,4-diones was reported but did not 
succeed in our lab 
16
. However, considerably better results were obtained through cyclodehydration via polyphosphoric 
acid (PPA) 
16, 32
. The advantages of this method were that the yields were considerably high, the method was less time-
consuming, and it was possible to purify the product by recrystallization 
32
. Accordingly, cyclodehydration of 1-substituted-
8-[2-(4-substituted phenyl)-2-oxoethylsulfanyl]-3,7-dihydro-1H-purine-2,6-diones 9a-g and 10 a-g was carried out in PPA 
as described in previous works 
16, 32
 at 130-140ºC for 5-6 h (except for 9f and 10f were heated at 110-120 ºC for 7-8 h) 
afforded the target compounds 3-(2-substituted benzyl)-6-(4-substituted phenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 11a-g 
and 12a-g. 
Chemical structures of the derivatives 11a-g and 12a-g were proved by IR, 
1
H NMR, EI-MS and ESI-HRMS. The purity of 
the prepared compounds was checked by TLC and further confirmed by elemental analyses. IR spectra of the new 
compounds 11a-g and 12a-g are characterized by disappearance of N7-H stretching band at 3350-3495 cm
-1
 which was 
taken as evidences for cyclization. 
1
H NMR spectra of compounds 11a-g and 12a-g showed the N1-CH2 protons as a singlet at δ 4.89-5.10 ppm integrating 
for two protons and N3-H at δ 12.00-12.50 ppm which was exchangeable with D2O. It also showed disappearance of the 
methylene protons of S-CH2 and the N7-H proton, in addition to the appearance of C7-H as downfield proton at 7.10-7.40 
ppm which are strong evidences for ring cyclization. Some of them were further confirmed by MS (see exp. part), for 
example, EI-MS of compound 11c showed the molecular ion peak M
+
 at m/z 408.05 (62.43%) corresponding to its relative 
molecular mass (408.04) and a base peak at m/z 91.05 (100%) in addition to M
+
+2 peak at m/z 410.00 (25.32%), due to 
37
Cl and the 
34
S. Also, 12b showed molecular ion peak M
+
 at m/z 469.90 (87.15%) corresponding to its relative molecular 
mass (469.98), a base peak at m/z 109.00 (100%) in addition to the M
+
+2 peak at m/z 471.90 (77.97%), due to 
81
Br and 
the 
34
S. 
Preparation of 3-substituted benzyl-5-methyl-7-substituted-1H-pyrido[2,3-d]pyrimidine-2,4-dione 13a-c and 14a-c was 
achieved by condensation of 6-amino-3-(2-substituted benzyl)-1H-pyrimidine-2,4-dione 1a or 1b and the appropriate 
acylacetone derivative in glacial acetic acid through refluxing for 3-4 h. 
Although the possibility existed that the condensation might have occurred through the nitrogen of the pyrimidine ring to 
give pyrimido[1,2-c]pyrimidine B rather than pyrido[2,3-d] pyrimidine A, this possibility is eliminated, Chart 3. If we had 
structure B for such product, C5-H would appear at δ 4.60-4.70 ppm in 
1
H NMR which disappeared in our case, and this 
confirms the condensation at C5 and N6-H2. Also, the presence of N1-H around δ 10.33-11.99 ppm in 
1
H NMR confirm 
this condensation pathway. Further confirmation to eliminate this possibility is proved in our lab by reaction of 1,3-
disubstituted uracil to block this pathway and gave the pyrido[2,3-d]pyrimidine derivatives 
33
. 
Chemical structures of the new derivatives 13a-c and 14a-c were proved by IR, 
1
H NMR, EI-MS and ESI-HRMS. The 
purity of the prepared compounds was checked by TLC and further confirmed by elemental analyses. IR spectra of the 
new compounds 13a-c and 14a-c are characterized by presence of characteristic bands at 3350-3430 cm
-1
 of (N-H) and 
at 1645-1710 cm
–1
 of (C=O) groups. Moreover, they showed the characteristic bands at 3050–3185 cm
–1
 (Ar-H stretching) 
in addition to its bending at 690-835 cm
–1
. 
1
H NMR spectra of compounds 13a-c and 14a-c, showed disappearance of 
both uracil C5-H at δ 4.60-4.70 ppm and N6-H2 at δ 6.17-6.22 ppm and the appearance of C6-H at δ 6.63-7.75 ppm and 
N1-H at δ 10.33-11.99 ppm which are strong evidences for ring cyclization. It is also characterized by the appearance of a 
methyl group at δ 2.70-3.03 ppm. Also, the structure of representative target compounds 13a-c and 14a-c was confirmed 
by EI-MS (see experimental part). For example, EI-MS of compound 14a revealed the molecular ion peak M
+
 at m/z 
299.00 (48.23%) corresponding to its relative molecular mass (299.11) and a base peak at m/z 109.00 (100%). Also, 14c 
showed the molecular ion peak M
+
 at m/z 394.90 (26.90%) corresponding to its relative molecular mass (395.08) and a 
base peak at m/z 109.00 (100%) in addition to M
+
+2 peak at m/z 396.90 (10.13%), due to 
37
Cl. 
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Chart 3; The possible cyclization pathways 
4.2.  Anticancer activity: 
The target compounds 4a, 4b, 6c, 7c, 9c, 10a, 10c, 12a, 13a, 13b and 14a were chosen to test for their anticancer activity 
against human breast cancer cell line MCF-7 in comparison to Doxorubicin (DOX) using the Sulphorhodamine-B (SRB) 
assay, after 72 h exposure 
30
. The data were fitted to sigmoidal concentration response curves and the corresponding IC50 
values were calculated using commercially available software (GraphPad Prizm). Most of the tested compounds showed 
good to excellent inhibition activity against the tested cell line in comparison to DOX, Table 1. It was noticed that 
compounds 7c (X= F, R= Br) and 9c (X= H, R
1
= Cl) were the most potent cytotoxic agents with IC50 value of 8.87, 7.25 
µmol/mL respectively (IC50 of DOX is 7.73 µmol/mL). 
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Moreover, compounds 10c (X= F, R
1
= Cl), 12a (X= F, R
1
= H), 13a (X= H, R= CH3) and 13b (X= H, R= C6H5) showed good 
cytotoxic activity compared to DOX as they showed IC50 value of 10.04, 14.00, 13.41 and 11.98 µmol/mL respectively 
(IC50 of Doxorubicin is 7.73 µmol/mL). 
From these data, it was concluded that (1) The phenacyl bromide derivative 9c (X= H, R
1
= Cl, with IC50 of 7.25 µmol/mL), 
was more active than the anilide derivative 7c (X= F, R= Br, with IC50 of 8.87 µmol/mL). (2) Cyclization of the phenacyl 
bromide derivative 10a (X= F, R
1
= H, with IC50 of 56.82 µmol/mL) into the corresponding thiazolopurine 12a (with IC50 of 
14.00 µmol/mL) emphasizes the importance of cyclization and addition of thiazole ring for anticancer activity. (3) Results 
also showed the significance of pyridopyrimidines 13a (X= H, R= CH3) and 13b (X= H, R= C6H5) as anticancer agents as 
they were potent cytotoxic agent. (4) Benzyl derivatives are more active than the fluorobenzyl derivatives as in some 
cases the insertion of the fluoro substituent decreased the activity, such as:  4a (X= H, IC50 of 15.64 µmol/mL) compared 
to 4b (X= F, IC50 of 19.95 µmol/mL), also, 9c (X= H, R
1
= Cl, IC50 of 7.25 µmol/mL) compared to 10c (X= F, R
1
= Cl, IC50 of 
10.04  µmol/mL) and 13a (X= H, R= CH3, IC50 of 13.41 µmol/mL) compared to 14a (X= F, R= CH3, IC50 of 69.5 µmol/mL). 
In other cases, the introduction of fluoro substituent increased the activity as shown in 6c (X= H, R= Br, IC50 of 18.35 
µmol/mL) and 7c (X= F, R= Br, IC50 of 8.87 µmol/mL).   
4.3. Molecular Modeling Study 
4.3.1. HipHop Pharmacophore 
Accelrys Discovery Studio Software package (DS) was used for automated ligand-based pharmacophore generation. 
HipHop is intended to derive common feature pharmacophore models using information from a set of active compounds. 
The retrieved pharmacophore models are expected to discriminate between active and inactive compounds. HipHop 
identifies configurations or three-dimensional spatial arrangements of chemical features that are common to molecules in 
a training set. The configurations are identified by a pruned exhaustive search, starting with small sets of features and 
extending them until no larger common configuration is found. The resultant pharmacophores are ranked as they are built. 
The ranking is a measure of how well the molecules map onto the proposed pharmacophores, as well as the rarity of the 
pharmacophore model. If a pharmacophore model is less likely to map to an inactive compound, it will be given a higher 
rank 
34-36
. In our study, we focused on ligand-based virtual screening techniques to identify novel compounds with activity 
for CDK1 inhibitors. We started the development of ligand-based pharmacophore models based on training set 
compounds with high activity (IC50 <1000 nM) and several-fold selectivity for CDK1. Afterward, the model was carefully 
and iteratively refined with exclusion volume spheres (XVOLs) and shape constraints. The final model was used to 
virtually screen in house database. In order to implement this modeling work-flow, a dataset of 30 active and 15 
biologically inactive compounds was collected from the literature based on chemical structure and CDK1 in vitro biological 
diversity, Table 2 
37-50
. 
Table 2: Data set of 30 training set of CDK1 inhibitors 
 
(1) Purvalanol A 
 
(2) Purvalanol B 
 
(3) NU6102 
 
(4) PMC104 
 
 
(5) CGP 60474 
 
(6) PMC122 
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(7) CGP74514A 
 
 
(8) RO-3306 
 
(9) PMC134 
 
(10) SU 9516 
 
(11) Indirubin-5-sulfonic 
acid 
 
(12) PMC148 
 
(13) PMC110 
 
(14) PMC152  
(15) PMC155 
 
 
(16) Aloisine A 
 
 
 
(17) Meridianin E 
 
(18) PMC111 
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(19) Flavopiridol 
 
 
(20) Kenpaullone  
(21) Roscovitine 
 
 
(22) PMC102 
 
 
 
(23) PMC103 
 
 
(24) PMC133 
 
 
(25) PMC147 
 
 
 
 
(26) PMC101 
 
(27) CVT-313 
 
 
(28) PMC153 
 
 
(29) Olomoucine 
 
 
(30) Indirubin 
 
In order to generate the best model, a lot of HipHop runs were carried out by varying the control parameters. In the model 
generation methodology, the highest weighing was assigned to the most active compound in the training set (Purvalanol 
A; IC50 1 μM), this was achieved by putting 2 (which ensures that all of the chemical features in the compound will be 
considered in building hypotheses space) and 0 (which forces mapping of all features of compound) in principle and 
maximum omitting features columns, respectively. For the moderately active compounds (IC50 < 10 nM), the value of 1 
(ensures that at least one mapping for each of generated hypotheses will be found) and 1 (all but one feature must map) 
were put in principle and maximum omitting feature column respectively. For the lower active compounds the value of 0 
(indicates that the molecule is inactive and will not be used in the creation of the pharmacophore) and 1 were put in 
principle and maximum omitting feature column respectively. Feature Mapping protocol was used to identify the common 
chemical groups present in the training set compounds. As predicted, hydrogen bond acceptor (HBA), Hydrogen Bond 
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Donor (HBD), Hydrophobic (HY), and Ring_Aromatic (RA), Positive_Ionizable, Negative_Ionizable features were selected 
during the pharmacophore generation. 
The successful HipHop run resulted in the generation of 10 hypotheses, each composed of four features, The 10 
hypotheses (Hypos) generated had scores from 173.292 to 166.657, Table 3. 
This small range of ranking score suggests that the features are spatially arranged in a similar fashion in all 10 models. To 
determine the similarity between the ten hypotheses, a hierarchical cluster analysis was performed. The results of the 
cluster analysis indicate that hypos 1 and 10 belong to the same cluster, whereas hypos 2, 3, 4, 5, 6, 7, 8 and 9 are 
slightly different. All ten hypotheses contain four features, of which one ring aromatic (RA) feature and one Hydrophobic 
(HY) are common for all except Hypo 6 which has no RA feature. The first two hypotheses show close statistics in terms of 
their rank score which is quite significantly better than the rest hypotheses. Consequently, both hypotheses (Hypo-1 and 
Hypo-2) were considered for further analysis. 
Table 3: Summary of HipHop generated common feature hypothesis: 
Hypothesis 
Features 
(a)
 
Rank 
Score 
Direct Hit 
(b)
 Partial Hit 
(c)
 
01 RHHA 173.292 011111111111110111101111 100000000000001000010000 
02 RRHA 173.126 111111001111110111111111 000000110000001000000000 
03 RRHA 171.971 111111011011110111111111 000000100100001000000000 
04 RRHA 171.971 111111011011110111111111 000000100100001000000000 
05 RRHA 170.761 111111011011110111111111 000000100100001000000000 
06 HHDA 170.656 010111111111110111111111 101000000000001000000000 
07 RHAA 168.541 110111011111110111111111 001000100000001000000000 
08 RHAA 168.068 110111011111110111111111 001000100000001000000000 
09 RHAA 166.659 110111011111110111111111 001000100000001000000000 
10 RHHA 166.657 011111011111110111111111 100000100000001000000000 
(a) R, Ring Aromatic; H, hydrophobic; A, hydrogen bond acceptor. 
(b) Direct hit indicates whether (1) or not (0) a molecule in the training set mapped to every feature in the 
hypothesis. 
(c) Partial hit indicates whether (1) or not (0) a molecule in the training set mapped to all but one feature in the 
hypothesis. 
4.3.2. Analysis of Hypo-1 and Hypo-2 
Examination of Hypo-1, Fig. 1,A shows two hydrophobic features (HY-1 and HY-2), a hydrogen bond acceptor (HBA) and 
a ring aromatic feature (RA). The two hydrophobic features are apart from each other by inter-feature distance of 4.5 Å. As 
for the Hypo-2, Fig. 1,B, the four features are somewhat different showing one hydrophobic feature (HY-1) and two ring 
aromatic features (RA-1 and RA-2) and with a hydrogen bond acceptor feature. The tested compounds were mapped 
onto Hypo-1 and Hypo-2 using the "best fit" option where HipHop scores the orientation of a mapped compound within the 
hypothesis features using a "fit value" score. For models that show four features, as in this case, the maximum fit value 
score is 4.0. 
 
Figure 1,A: Hypo-1 showing inter-feature distances (Å), B: Hypo-2 showing inter-feature distances (Å). 
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Features are colour coded as: Hydrophobic, cyan; Hydrogen bond acceptor, green, Ring Aromatic, orange. 
Results from the mapped compounds, Table 4 showed a rough correlation between the fit values and their biological 
activities. The most active compound (Purvalanol A) was assigned the highest fit value by both models. However both 
models can not differentiate between the small differences in biological activity exhibited by the rest of the active 
compounds. Mapping of compound (Purvalanol A) to both models (Hypo-1 and Hypo-2) is shown in Fig. 2. 
Table 4: Output for Hypo-1 and Hypo-2 mapping 
Compound IC50 (nM) 
Fit value E (kcal/mol) 
a
 
Hyp-1 Hyp-2 Hyp-1 Hyp-2 
Purvalanol A 0.0040 3.99982 3.99990 18.15480 19.43690 
Purvalanol B 0.0060 3.43070 3.68802 5.38114 10.32610 
NU6102 0.0095 2.64262 0.76285 4.43556 13.03910 
PMC104 0.0180 2.57900 3.05038 10.78220 19.98450 
CGP 60474 0.0200 3.20182 3.32401 2.34222 14.29670 
PMC122 0.0200 2.99200 2.82664 18.28480 10.72110 
CGP74514A 0.0250 2.23308 2.16324 11.80130 15.54800 
RO-3306 0.0350 2.75914 3.06869 13.46750 8.71847 
PMC134 0.0370 1.88601 2.53830 15.88930 18.65870 
SU 9516 0.0400 2.37105 2.86794 1.27289 0.03687 
Indirubin-5-sulfonic acid 0.0550 2.35306 1.97079 0.13574 0.03119 
PMC148 0.0790 3.09696 1.06825 11.16860 10.92790 
PMC110 0.1000 2.65747 2.45176 12.36690 18.14150 
PMC152 0.1200 1.05235 0.78202 1.60350 1.59593 
PMC155 0.1500 2.70099 1.75875 1.49593 2.64313 
Aloisine A 0.1500 1.00974 0.59599 0.03732 0.76521 
Meridianin E 0.1800 2.54131 2.32808 3.70928 0.15680 
PMC111 0.2400 2.39782 2.26169 2.07870 13.63680 
Flavopiridol 0.3000 3.05840 2.47295 14.60780 18.90930 
Kenpaullone 0.4000 0.12510 1.54723 0.00162 0.00162 
Roscovitine 0.4500 3.24415 3.00109 7.94801 8.75622 
PMC102 0.4800 2.55044 2.60564 6.96686 2.56536 
PMC103 0.4800 2.33536 2.41849 7.66487 11.17070 
PMC133 0.7800 2.72069 2.53458 2.52811 15.85060 
PMC147 1.0000 1.13752 1.27160 0.00000 0.00000 
PMC101 1.9000 2.86885 1.99229 13.10650 3.04452 
CVT-313 4.2000 2.02903 3.03385 2.45691 7.17578 
PMC153 6.0000 2.19827 1.02872  .505543 0.00000 
Olomoucine 7.0000 2.64728 3.22910 7.75201 7.75201 
Indirubin 10.0000 2.31198 1.49944 0.00000 0.00000 
(a) Relative energy of the fitted conformer. 
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Figure 2. Mapping of (Purvalanol A) (stick) to (A) Hypo-1 and (B) Hypo-2. 
Mapping of all compounds reveals the predominance of Hypo-1 over Hypo-2 in mapping of the training set and also 
showed the importance of presence of certain groups to fit the produced model. The two hydrophobic features (HY-1 and 
HY-2) can accommodate either an aromatic ring, cycloalkyl, alkyl and halogen groups. The hydrogen bond acceptor 
feature (HBA) is occupied by carbonyl, sulfonyl or heteroatom within aromatic ring. Ring aromatic features (RA-1) 
accommodate five or six membered aromatic rings. 
4.3.3. Screening of in-house dataset of newly synthesized compounds: 
Mapping the dataset of the 50 synthesized compounds to Hypo-1 using Ligand Pharmacophore Mapping Protocol was 
done to investigate the activity of the synthesized Ligands against CDK1, as anticancer candidates shown that of the 50 
compounds, 46 compounds mapped to the Pharmacophore Model with different fit values. The most active compound (9c) 
in the anticancer assay showed the best fit value, Fig. 3, however there was a rough correlation between the anticancer 
activity and the rest of the tested compounds, Table 5. Generally, theoretical suggestion is comparable to some extent 
with the practical one. 
Table 5:  Fit value for the tested synthesized compounds against Hypo-1 together with anti-proliferative activity 
against  
MCF-7 as IC50 
Compound IC50 (μmol/mL) Fit value 
9c 7.25 3.57403 
7c 8.87 3.48897 
10c 10.04 2.98574 
13b  11.98 2.76242 
13a 13.41 2.75817 
12a 14.00 2.79434 
4a 15.64 2.39551 
6c 18.35 3.36915 
4b  19.95 2.36067 
10a 56.82 2.87789 
14a 69.54 2.77761 
 
 
         I S S N  2 3 2 1 - 8 0 7 X  
              V o l u m e  1 3  N u m b e r  2  
     J o u r n a l  o f  A d v a n c e s  i n  c h e m i s t r y  
 
 5973 | P a g e 
A p r i l  2 0 1 7                                        w w w . c i r w o r l d . c o m 
 
 
Figure 3. Mapping of (9c) (stick) to Hypo-1. 
4.4.  Flow Cytometric Analysis 
On the basis of the in-vitro cytotoxicity data, the most potent compounds 6c, 7c, 9c, 10c, 12a, 13a and 14a against MCF-7 
cells line were selected for further mechanistic study. MCF-7 cells were not only treated with DMSO (0.1%) alone as 
controls, but were treated with two concentrations of each tested compounds (at 25 μmol/mL and at each ones's 
corresponding IC50 in μmol/mL) for 24 h and stained with propidium iodide (PI). The effects on cell cycle distribution of 
MCF-7 cells were evaluated by flow cytometry. The inhibition of cancer cell proliferation, the cessation of cell cycle 
progression, and the induction of apoptosis have all been targeted in chemotherapeutic strategies for the treatment of 
cancer. We therefore evaluated whether tested compounds alter the cell cycle of MCF-7 cells using PI and flow cytometric 
analyses, Table 6. Figure 4 shows representative experiment; we found that the percentage of apoptotic cells was 
comparable to 3% in the untreated cells. Treatment with tested compounds showed 27.74-51.60% as percentage of 
apoptotic cells at the IC50 of tested compounds, and from 33.90-47.99% of apoptotic cells at a concentration of 25 
μmol/mL. This increased induction of apoptosis after treatment with tested compounds was inversely correlated with a 
significant decrease in the percentage of cells in S phase. The total data from different experiments (n = 70 for MCF-7 
cells) demonstrated that treatment with tested compounds significantly potentiated apoptosis in MCF-7 cells (Table 6). It 
can be seen that there is no great difference in induction of apoptosis between the two concentrations of the tested 
compounds either at the IC50 or at a concentration of 25 μmol/mL which eliminate the importance of high dosage of the 
compounds to prevent toxicity.    
Table 6:  Flowcytometric analysis 
Compound Apoptosis % at 
corresponding 
IC50  
Apoptosis % at 25 
μmol/mL 
6c 40.74% at 18.35 
μmol/mL 
45.16% 
7c 51.60% at 8.87 
μmol/mL 
 
 
4.46 μg/mL 
45.68% 
9c 42.32% at 7.25 
μmol/mL 
41.80% 
10c 51.59% at 10.04 
μmol/mL 
45.36% 
12a 49.61% at 14.00 
μmol/mL 
47.99% 
13a 
34.31% at 13.41 
μmol/mL 
33.90% 
14a 
27.74% at 69.54 
μmol/mL 
37.24% 
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Figure 4, The ability of representative compounds to alter cell cycle; 
A: DMSO, B: 13a at 25 μmol/mL, C: 13a at its IC50 (13.41 μmol/mL)  
5. CONCLUSION 
In the present work, the synthesis of thiazolo[2,3-f]purine-2,4-diones 11a-g and 12a-g and their isosteres pyrido[2,3-
d]pyrimidine-2,4-diones 13a-c and 14a-c were designed and synthesized. The proposed structures of the new compounds 
were confirmed by spectroscopic and elemental analyses. The anticancer activity of most of the newly synthesized 
compounds showed good to excellent inhibition activity against the tested human breast cancer cell line MCF-7 in 
comparison to doxorubicin as a reference drug. 
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